Premium
Efficacy of icotinib in lung squamous‐cell cancer: A real‐world experience from single institution
Author(s) -
Xu Jianping,
Liu Xiaoyan,
Yang Sheng,
Zhang Xiangru,
Shi Yuankai
Publication year - 2017
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12669
Subject(s) - medicine , lung cancer , oncology , clinical endpoint , survival rate , epidermal growth factor receptor , cancer , gastroenterology , randomized controlled trial
Aim Squamous cell carcinoma is a less common type of nonsmall cell lung cancer (NSCLC) which associates with a poor clinical prognosis and lacks specific therapy. This study aimed to evaluate the efficacy and safety of icotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has proven to be effective in EGFR‐mutated NSCLC, in patients with lung squamous‐cell cancer. Methods Retrospective analysis was conducted in patients who had advanced lung squamous‐cell cancer confirmed by cytology or histology. Patients were treated orally with icotinib (125 mg, three times daily) until event of unacceptable toxicity, disease progression or death. The primary endpoint was overall survival. The secondary endpoints were progression‐free survival, overall response rate and disease control rate. Results Between January 2014 and May 2016, 20 patients were enrolled and evaluated for the efficacy and safety of icotinib. Overall, the median overall survival and progression‐free survival were 9.93 months (95% confidence interval (CI): 3.46–16.40) and 3.0 months (95% CI: 0.00–8.35), respectively. The overall response rate and disease control rate were 20% and 70%, respectively. For treatment‐naive patients ( n = 11), the overall survival and progression‐free survival were 9.93 months (95% CI: 0.00–23.49) and 6.27 months (95% CI: 0.00–12.61); the response rate and disease control rate were 27.3% and 54.5%, respectively. The overall survival and progression‐free survival of patients treated with second‐ or multiple‐line icotinib treatment ( n = 9) were 6.5 months (95% CI: 0.80–12.20) and 1.2 months (95% CI: 1.10–1.30). A total of 11 patients experienced at least one treatment‐related adverse event, most of which were mild to moderate. The most common manifestations were rash ( n = 6, 30%) followed by diarrhea ( n = 2, 10%). Conclusion Icotinib has demonstrated a favorable efficacy and safety profile in patients with advanced lung squamous‐cell cancer.